I Say Again...... muddyc | NVAX Message Board Posts


    30% off entry-level Bronze Patron packages (retails for $250 - reduced to $175)
    includes 2 yrs of Premium Plus service & locks in 30% discount for any future Patron upgrades

    Only 35 spots available (first come, first served)

    BONUS: Purchase your spot over the next 24 hrs & get an extra year of Premium Plus service absolutely free! 

    CLICK HERE to become a Bronze Patron now 

NVAX   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  63582 of 69601  at  6/19/2019 1:25:39 PM  by


 In response to msg 63579 by  muddyc
view thread

Re: I Say Again...... muddyc

You beat me to it. They would have missed the 30% LL if they had fully enrolled the 8618 patients. If the efficacy data would have stayed the same, they would have failed with patients enrollment of 8618, or 16,000, or 32,000. They would have failed even if they hadn't done the early look and taken the alpha penalty.
Obviously, we don't know what attack rates would have been seen with an extended trial (a different season). It would have been a crapshoot. The efficacy for that added season would have to have been much higher than the 39/40% seen for even the expanded data. 
One could argue that they made a lucky choice when they received the partial data from the early look. If they had obtained the complete topline data for the 4636 patients at the time of the early look, would they have made the decision to continue enrolling to the 8618? I think not. They missed the FDA mark by a wide margin and would have had to get great results in the next 4000 patients.
Since this vaccine has shown it "works", then maybe the original trial design was screwed up (patient numbers, end points, vaccination time, etc.). How would one design a repeat trial? Promoting one of the secondaries as the primary endpoint MIGHT help, but the original endpoint might give the best result in a trial repeat. Surrogate endpoints would be a hard sell. A much higher number of patients would certainly help (funding).  The numbers of events, even with the expanded exploratory data, seems very small.
NVAX remarking that the AR was comparable to that of the early look was something that would be unthinkable for well-run companies. Heinous. When you listen to NVAX investor presentations, you can "hear" the problems with the top of the organization.
So what's happening with the EU and expanded data, or has it already happened? 

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 476
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
63616 Re: I Say Again...... muddyc goirish1776 1 6/20/2019 1:02:29 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
Financial Market Data provided by